title: A prospective study of body weight and serum leptin levels in patients treated with topiramate.
abstract: OBJECTIVE
  We prospectively studied 26 (10 women) patients (age, 37.4 +/- 10.3 years) with different types of refractory focal epilepsy who received topiramate as adjunctive treatment.
  
  
  METHODS
  Body mass indices (BMI, kg/m2) and serum leptin levels (SLL) were investigated at baseline (n = 26) and 9.5 +/- 2.9 (T1; n = 21) and 25.0 +/- 3.5 (T2; n = 18) weeks after initiation of topiramate.
  
  
  RESULTS
  We found significant reductions in BMI (T1, -0.4 +/- 0.7; T2, -1.3 +/- 2.1 kg/m2) but not in SLL, although a tendency for reduced SLL was observed for women. Serum leptin level changes were mostly within the range between fifth and 95th sex-specific BMI-adjusted reference percentiles. Significant inverse correlations were found between baseline values and changes in both BMI (T2; r = -0.76; P < 0.001) and SLL (T2; r = -0.65; P = 0.003). Patients with BMI of 30.0 kg/m2 or greater showed the highest weight loss at T2 (-4.8 +/- 3.2 kg/m2).
  
  
  CONCLUSIONS
  Our findings do not provide evidence for a direct causal involvement of leptin in topiramate-related weight loss.
authors.affiliation: Department of Child and Adolescent Psychiatry, University of Marburg, Marburg, Germany.
authors.forename: Frank M
authors.initials: FM
authors.lastname: Theisen
authors.forename: Stefan
authors.initials: S
authors.lastname: Beyenburg
authors.forename: Stefan
authors.initials: S
authors.lastname: Gebhardt
authors.forename: Michael
authors.initials: M
authors.lastname: Kluge
authors.forename: Werner F
authors.initials: WF
authors.lastname: Blum
authors.forename: Helmut
authors.initials: H
authors.lastname: Remschmidt
authors.forename: Christian E
authors.initials: CE
authors.lastname: Elger
authors.forename: Johannes
authors.initials: J
authors.lastname: Hebebrand
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects; D000328:Adult; D000368:Aged; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects* / Q000502:physiology; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000188:drug therapy; D011446:Prospective Studies; D012737:Sex Factors; D000077236:Topiramate
chemical_list: D019440:Anti-Obesity Agents; D000927:Anticonvulsants; D020738:Leptin; D000077236:Topiramate; D005632:Fructose